

# Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

## DLD-1

RRID:CVCL\_0248

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_0248

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0248](https://web.expasy.org/cellosaurus/CVCL_0248)

**Proper Citation:** RRID:CVCL\_0248

**Description:** Cell line DLD-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Colon adenocarcinoma

**Defining Citation:** [PMID:427742](#), [PMID:2041050](#), [PMID:3335022](#), [PMID:6652615](#), [PMID:7247963](#), [PMID:7621404](#), [PMID:7651727](#), [PMID:7874267](#), [PMID:7972006](#), [PMID:8197130](#), [PMID:8422623](#), [PMID:8464898](#), [PMID:9290701](#), [PMID:9294210](#), [PMID:9515795](#), [PMID:9809040](#), [PMID:10612807](#), [PMID:10674020](#), [PMID:10700188](#), [PMID:11226274](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:11668190](#), [PMID:12068308](#), [PMID:12615714](#), [PMID:16418264](#), [PMID:16854228](#), [PMID:18258742](#), [PMID:19927377](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22460905](#), [PMID:22490663](#), [PMID:23272949](#), [PMID:24042735](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25841592](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26295583](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:28179481](#), [PMID:28192450](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:29101300](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32172478](#)

**Comments:** Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** DLD-1

**Synonyms:** DLD 1, DLD1, CoCL3

**Cross References:** BTO:BTO\_0000391, CLO:CLO\_0002785, EFO:EFO\_0006389, MCCL:MCC:0000138, CLDB:cl1065, CLDB:cl1066, AddexBio:C0009007/36, ArrayExpress:E-MTAB-2706, ATCC:CCL-221, BCRC:60132, BioGRID\_ORCS\_Cell\_line:158, BioSample:SAMN01821551, BioSample:SAMN01821680, BioSample:SAMN03472323, cancercellines:CVCL\_0248, CCRID:1101HUM-PUMC000671, CCRID:3101HUMTCHu134, CCRID:4201HUM-CCTCC00620, Cell\_Model\_Passport:SIDM00787, ChEMBL-Cells:ChEMBL3307580, ChEMBL-Targets:ChEMBL614285, CLS:300220, ColonAtlas:DLD1, Cosmic:687519, Cosmic:755307, Cosmic:870451, Cosmic:873699, Cosmic:876713, Cosmic:905005, Cosmic:913890, Cosmic:934560, Cosmic:948123, Cosmic:983737, Cosmic:985994, Cosmic:1043810, Cosmic:1066204, Cosmic:1122323, Cosmic:1154643, Cosmic:1175839, Cosmic:1184082, Cosmic:1184331, Cosmic:1187305, Cosmic:1223137, Cosmic:1310949, Cosmic:1466813, Cosmic:1479591, Cosmic:1481418, Cosmic:1519360, Cosmic:1524004, Cosmic:1552176, Cosmic:1571767, Cosmic:1609511, Cosmic:1676737, Cosmic:1805251, Cosmic:2301544, Cosmic:2301972, Cosmic:2389573, Cosmic:2464668, Cosmic:2550352, Cosmic:2646769, Cosmic:2650774, Cosmic:2651870, Cosmic:2664050, Cosmic:2667971, Cosmic:2668249, Cosmic:2727471, Cosmic:2727478, Cosmic:2760067, Cosmic:2787544, Cosmic:2811050, DepMap:ACH-001061, DSMZ:ACC-278, DSMZCellDive:ACC-278, ECACC:90102540, EGA:EGAS00001000610, EGA:EGAS00001002554, ENCODE:ENCBS580BTU, ENCODE:ENCBS621AWM, GEO:GSM206467, GEO:GSM274715, GEO:GSM274716, GEO:GSM274727, GEO:GSM513817, GEO:GSM514291, GEO:GSM741247, GEO:GSM886979, GEO:GSM888048, GEO:GSM1346869, GEO:GSM1374463, GEO:GSM1448161, GEO:GSM1696579, GEO:GSM1696580, GEO:GSM1696581, GEO:GSM1696582, GEO:GSM2549997, IARC\_TP53:18, ICLC:HTL95011, JCRB:JCRB9094, KCB:KCB 2011096YJ, KCLB:10221, LINCS\_LDP:LCL-1175, Lonza:806, MetaboLights:MTBLS227, PharmacDB:DLD1\_294\_2019, PRIDE:PXD000218, PRIDE:PXD001550, PRIDE:PXD005354, PRIDE:PXD005355, Progenetix:CVCL\_0248, PubChem\_Cell\_line:CVCL\_0248, RCB:RCB1957, SKY/M-FISH/CGH:1992, SKY/M-FISH/CGH:2763, TKG:TKG 0379, TOKU-E:1078, Wikidata:Q54831148

**ID:** CVCL\_0248

**Hierarchy:** cvcl\_3449

**Record Creation Time:** 20220427T215819+0000

**Record Last Update:** 20260829T232540+0000

---

## Ratings and Alerts

No rating or validation information has been found for DLD-1.

**Warning:** Discontinued: RCB; RCB1957

Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

---

## Data and Source Information

## Usage and Citation Metrics

We found 1461 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Liang X, et al. (2026) Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis. *Cell death discovery*, 12(1), 92.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. *Cell reports*, 45(2), 116956.

Bloomfield M, et al. (2026) Cell and Nuclear Size Is Associated with Chromosomal Instability and Tumorigenicity in Cancer Cells That Undergo Whole Genome Doubling. *Cancer research*, 86(9), 2126.

Li G, et al. (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. *Cell metabolism*, 38(1), 174.

Renner F, et al. (2026) Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer. *Molecular cancer therapeutics*, 25(4), 599.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Li D, et al. (2026) ASCL2 drives colorectal cancer metastasis through transcriptional activation of TDGF1. *Cellular oncology (Dordrecht, Netherlands)*, 49(3).

Ebata Y, et al. (2026) Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer. *Molecular oncology*.

Chen B, et al. (2026) BRD4-mediated ER membrane contact creates functionally distinct mitochondrial subtypes. *Molecular cell*, 86(5), 917.

Fu D, et al. (2026) ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(26), e16557.

Okamoto R, et al. (2026) Transgelin Expression in Activated Cancer-Associated Fibroblasts Regulates Stromal Contractility and Promotes Colon Cancer Progression. *Cancer medicine*, 15(4), e71789.

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. *bioRxiv : the preprint server for biology*.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. *iScience*, 29(6), 115978.

Sar??o??lu AO, et al. (2026) Eu(III), Tb(III), and Gd(III) Complexes With Dual Ligand Architecture: Synthesis, Characterization, Photoluminescence, Cytotoxic, and Molecular Docking Studies. *Chemistry & biodiversity*, 23(7), e71502.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.

Lakha R, et al. (2026) Comparison studies between Cesium-137 and X-ray irradiators in epithelial injury using in vitro and in vivo models. *bioRxiv : the preprint server for biology*.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. *Oncology research*, 34(2), 20.

Gao J, et al. (2026) AURKA-mediated destabilization of SAPS3 drives ferroptosis evasion via 7-dehydrocholesterol biosynthesis in colorectal cancer. *Cell death & disease*, 17(1).

Sorrenti E, et al. (2026) Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer. *Cell host & microbe*, 34(3), 425.